However, in a statement, the FDA stated the medications could cause joint pain that can be severe and disabling, and the company has added a fresh Warning and Precaution about this risk to labels of most medicines in this medication class. The FDA stressed that patients who have a DPP-4 inhibitor shouldn’t stop using the drug, but should contact their healthcare professional right away if indeed they experience severe and persistent joint pain. Doctors and other health-care employees should consider DPP-4 inhibitors as a possible reason behind severe joint pain and discontinue the drug if appropriate, the company said.Recognizing the potential differences in clinical presentation and long-term outcomes, and the potential dangers of aggressive therapy in pediatric individuals with thyroid malignancy overly, an ATA Task Push developed management guidelines for children with thyroid nodules and differentiated thyroid malignancy , which are published in Thyroid, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers and the official journal of the American Thyroid Association . The rules are available free on the Thyroid website. The ATA Guidelines Task Push on Pediatric Thyroid Malignancy, led by Seat Gary Francis, MD, PhD, Virginia Commonwealth University , and Co-Chairs Steven Waguespack, MD, University of Texas MD Anderson Cancer tumor Middle , and Andrew Bauer, MD, Children's Hospital of Philadelphia, PA, based their tips about an extensive review of the medical literature linked to clinical studies involving kids and adolescents 18 years or younger.